The system uses new technology to provide same-day results for whole-genome sequencing.
Roche announced the global launch of AXELIOS 1, a new single-molecule sequencing platform. The system utilizes the company’s proprietary sequencing by expansion (SBX) technology, which is designed to improve the accuracy and speed of genomic research.
The platform uses a biochemical process to convert deoxyribonucleic acid and ribonucleic acid (RNA) into polymers called “Xpandomers.” These polymers are 50 times longer than the original molecules, which allows the system to generate high signal-to-noise reports. These signals are measured by a reusable complementary metal-oxide-semiconductor sensor that contains millions of nanopores.
“AXELIOS 1 will deliver a disruptive sequencing solution that combines high accuracy with unprecedented speed and scalability,” says Matt Sause, CEO of Roche Diagnostics, in a release. “These attributes, combined with our high level of cost efficiency, will enable the sequencing community to develop applications that previously were not feasible.”
Platform Capabilities and Workflow
According to the company, the platform can complete end-to-end whole-genome sequencing within a single day. The system’s architecture allows laboratories to handle various project sizes, ranging from small studies to large-scale genomic research involving thousands of samples, without changing instruments or workflows. The technology also supports reads of up to approximately 1500 base pairs and provides near real-time analysis.
Roche launched the platform following collaborations with the Hartwig Medical Foundation and Broad Clinical Labs to verify its performance in real-world settings. The company is also working with 10x Genomics to provide kits for single-cell and spatial applications. For data analysis, the platform supports the SBX technology through Google DeepVariant and an open-source suite of tools known as XOOS.
Research and Future Clinical Use
While the system is focused on research today, the company indicates it may be used for clinical applications and personalized healthcare in the future. Early-access users have tested the technology for applications including RNA-sequencing, single-cell RNA, spatial analysis, and methylation across oncology, genetics, and infectious diseases.
The AXELIOS 1 platform is currently for research use only and is not intended for use in diagnostic procedures.
Photo caption: AXELIOS 1
Photo credit: Roche
